Cramer: The Tide's Turned for Drug Stocks: Jim Cramer discusses his thoughts about the biotech and pharmaceutical names that could be poised for gains.


Click here to watch the video.

Five Dirt-Cheap Stocks for Getting Filthy Rich: Stockpickr founder, James Altucher, says these dirt cheap stocks will make you serious money.

Click here to watch the video

Outperform - Price 40.05 on May 13
by Cowen & Co.

Upgrading to Outperform from Neutral. Although we still find very little to like about the Pliva acquisition, we believe most of the integration risk has now passed and Barr is about to enter what could be an exceedingly strong new U.S. product cycle....We believe that BRL shares are now undervalued....The opportunities are: (1) launch of Yasmin; (2) the Adderall XR launch in April '09; and (3) potential settlements and/or launches of Yaz, Ortho-Tricyclen Lo, Mirapex and Allegra D....BRL trades at a slight discount to group average, and we believe we are factoring a conservative case. EPS estimates: 2008, $2.90; 2009, $3.50. Market cap: $4.4 billion.

Barr Pharma (BRL) was upgraded from Neutral to Outperform, Cowen said. Risks are factored into the stock, and the company should soon enter a solid US product cycle.

homework

Generic drugs

the generics will be king

Underappreciated on a pullback

Upgraded by Bernstein from Mkt Perform to Outperform

growth in earnings and equity selling at a discount.

Is there any life in this generic drug company. Nope... it's dead.

New generic drugs in pipeline which are big money makers if they are able to bring on market.